Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Control. 2008 Jan;15(1):47-54.

Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas.

Author information

1
Sarcoma Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA. audrey.shor@moffitt.org

Abstract

BACKGROUND:

Sarcomas are rare mesenchymally derived tumors for which there are limited treatment options. This paper discusses the current therapeutic potential of directed tyrosine kinase inhibitors (TKIs) in sarcoma.

METHODS:

The authors review antibody-based strategies and small molecular inhibitors of TKIs, with specific emphasis placed on the potential use of these targeted agents as therapeutic options for the treatment of sarcomas that are not gastrointestinal stromal tumors.

RESULTS:

Many TKs have been shown to be mutated or overexpressed in human sarcoma tumors and cell lines and may serve as potential targets for promising new sarcoma therapies. Furthermore, the novel mechanism of targeting TKs may complement the antitumor activity of existing sarcoma treatment options.

CONCLUSIONS:

TKIs such as imatinib, sunitinib, and sorefanib are promising new therapeutic options for the management of patients with soft tissue sarcoma.

PMID:
18094660
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for H. Lee Moffitt Cancer Center and Research Institute
    Loading ...
    Support Center